688076 ST诺泰
已收盘 11-13 15:00:00
资讯
新帖
简况
ST诺泰(688076)9月30日股东户数1.41万户，较上期增加1.66%
证券之星 · 10-28
ST诺泰(688076)9月30日股东户数1.41万户，较上期增加1.66%
图解ST诺泰三季报：第三季度单季净利润同比下降10.72%
证券之星 · 10-28
图解ST诺泰三季报：第三季度单季净利润同比下降10.72%
ST诺泰(688076.SH)前三季净利润3.35亿元，同比下滑24.61%
中金财经 · 10-27
ST诺泰(688076.SH)前三季净利润3.35亿元，同比下滑24.61%
ST诺泰3865万收购亏损赛立成：关联收购暗藏多重疑云
新浪证券 · 09-24
ST诺泰3865万收购亏损赛立成：关联收购暗藏多重疑云
诺泰生物收购赛立成意欲何为？
中金财经 · 09-24
诺泰生物收购赛立成意欲何为？
股市必读：ST诺泰生物（688076）9月23日披露最新机构调研信息
证券之星 · 09-24
股市必读：ST诺泰生物（688076）9月23日披露最新机构调研信息
ST诺泰：9月23日召开业绩说明会，投资者参与
证券之星 · 09-23
ST诺泰：9月23日召开业绩说明会，投资者参与
ST诺泰(688076.SH)子公司拟3865万元收购赛立成100%股权
智通财经 · 09-15
ST诺泰(688076.SH)子公司拟3865万元收购赛立成100%股权
ST诺泰（688076）2026年中报简析：增收不增利
证券之星 · 08-27
ST诺泰（688076）2026年中报简析：增收不增利
ST诺泰(688076)6月30日股东户数1.39万户，较上期减少7.73%
证券之星 · 08-26
ST诺泰(688076)6月30日股东户数1.39万户，较上期减少7.73%
股市必读：ST诺泰新发布《ST诺泰：关于会计政策变更的公告》
证券之星 · 08-26
股市必读：ST诺泰新发布《ST诺泰：关于会计政策变更的公告》
图解ST诺泰中报：第二季度单季净利润同比下降45.64%
证券之星 · 08-26
图解ST诺泰中报：第二季度单季净利润同比下降45.64%
每周股票复盘：ST诺泰（688076）现1400万元大宗交易
证券之星 · 08-23
每周股票复盘：ST诺泰（688076）现1400万元大宗交易
8月21日ST诺泰现1400万元大宗交易
证券之星 · 08-21
8月21日ST诺泰现1400万元大宗交易
股市必读：ST诺泰（688076）新发布《中喜会计师事务所（特殊普通合伙）关于江苏诺泰澳赛诺生物制药股份有限公司2025年年度报告及2026年第一季度报告的信息披露监管问询函有关财务问题的回复》
证券之星 · 07-13
股市必读：ST诺泰（688076）新发布《中喜会计师事务所（特殊普通合伙）关于江苏诺泰澳赛诺生物制药股份有限公司2025年年度报告及2026年第一季度报告的信息披露监管问询函有关财务问题的回复》
ST诺泰（688076）披露2023年限制性股票激励计划第三个归属期归属结果暨股份上市公告，7月8日股价下跌0.91%
证券之星 · 07-08
ST诺泰（688076）披露2023年限制性股票激励计划第三个归属期归属结果暨股份上市公告，7月8日股价下跌0.91%
每周股票复盘：ST诺泰（688076）第三期限制性股票归属76.4万股
证券之星 · 06-28
每周股票复盘：ST诺泰（688076）第三期限制性股票归属76.4万股
ST诺泰（688076）披露2023年限制性股票激励计划第三个归属期符合归属条件的公告，6月26日股价下跌1.72%
证券之星 · 06-26
ST诺泰（688076）披露2023年限制性股票激励计划第三个归属期符合归属条件的公告，6月26日股价下跌1.72%
ST诺泰：公司自主研发的英克司兰注射液目前处于小试阶段
证券之星 · 06-03
ST诺泰：公司自主研发的英克司兰注射液目前处于小试阶段
ST诺泰：已与Incyte、Gilead等知名创新药企建立稳固合作关系
证券之星 · 06-03
ST诺泰：已与Incyte、Gilead等知名创新药企建立稳固合作关系
加载更多
公司概况
公司名称：
江苏诺泰澳赛诺生物制药股份有限公司
所属行业：
医药制造业
上市日期：
2021-05-20
主营业务：
江苏诺泰澳赛诺生物制药股份有限公司的主营业务是多肽药物及小分子化药的自主研发与定制研发生产。公司的主要产品是司美格鲁肽、利拉鲁肽、替尔泊肽、英克司兰、醋酸兰瑞肽、磷酸奥司他韦、胸腺法新。
发行价格：
15.57
{"stockData":{"symbol":"688076","market":"SH","secType":"STK","nameCN":"ST诺泰","latestPrice":27.58,"timestamp":1794553200000,"preClose":28.16,"halted":0,"volume":1757747,"delay":0,"changeRate":-0.0206,"floatShares":317000000,"shares":317000000,"eps":0.7039,"marketStatus":"已收盘","change":-0.58,"latestTime":"11-13 15:00:00","open":28.11,"high":28.18,"low":27.5,"amount":48827600,"amplitude":0.0241,"askPrice":27.66,"askSize":30,"bidPrice":27.58,"bidSize":10,"shortable":0,"etf":0,"ttmEps":0.7039,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1794792600000},"marketStatusCode":5,"adr":0,"adjPreClose":28.16,"symbolType":"stock_kcb","openAndCloseTimeList":[[1794533400000,1794540600000],[1794546000000,1794553200000]],"highLimit":29.57,"lowLimit":26.75,"ibTradeSell":true,"ibTradeBuySell":false,"totalEquity":316815961,"isCdr":false,"pbRate":2.71,"roa":"--","peRate":39.181702,"roe":"10.62%","epsLYR":1.06,"committee":-0.114391,"marketValue":8738000000,"turnoverRate":0.0055,"status":1,"afterMarket":{"amount":0,"volume":0,"close":27.58,"buyVolume":0,"sellVolume":0,"time":1794555237746,"indexStatus":"已收盘 11-13 15:30:00","preClose":28.16},"floatMarketCap":8738000000},"requestUrl":"/m/hq/s/688076","defaultTab":"news","newsList":[{"id":"2678346373","title":"ST诺泰(688076)9月30日股东户数1.41万户，较上期增加1.66%","url":"https://stock-news.laohu8.com/highlight/detail?id=2678346373","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678346373?lang=zh_cn&edition=full","pubTime":"2026-10-28 18:33","pubTimestamp":1793183602,"startTime":"0","endTime":"0","summary":"证券之星消息，近日ST诺泰披露，截至2026年9月30日公司股东户数为1.41万户，较6月30日增加230.0户，增幅为1.66%。在化学制药行业个股中，ST诺泰股东户数低于行业平均水平，截至9月30日，化学制药行业平均股东户数为3.9万户。从股价来看，2026年6月30日至2026年9月30日，ST诺泰区间涨幅为10.63%，在此期间股东户数增加230.0户，增幅为1.66%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102800040186.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688076","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678100476","title":"图解ST诺泰三季报：第三季度单季净利润同比下降10.72%","url":"https://stock-news.laohu8.com/highlight/detail?id=2678100476","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678100476?lang=zh_cn&edition=full","pubTime":"2026-10-28 03:39","pubTimestamp":1793129989,"startTime":"0","endTime":"0","summary":"证券之星消息，ST诺泰2026年三季报显示，前三季度公司主营收入17.47亿元，同比上升14.43%；归母净利润3.35亿元，同比下降24.61%；扣非净利润3.72亿元，同比下降14.89%；其中2026年第三季度，公司单季度主营收入6.08亿元，同比上升26.92%；单季度归母净利润1.2亿元，同比下降10.72%；单季度扣非净利润1.23亿元，同比下降6.19%；负债率55.1%，投资收益208.49万元，财务费用7811.98万元，毛利率57.61%。财报数据概要请见下图:本文数据来源于ST诺泰2026年三季报，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102800003190.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688076"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678108067","title":"ST诺泰(688076.SH)前三季净利润3.35亿元，同比下滑24.61%","url":"https://stock-news.laohu8.com/highlight/detail?id=2678108067","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678108067?lang=zh_cn&edition=full","pubTime":"2026-10-27 21:22","pubTimestamp":1793107327,"startTime":"0","endTime":"0","summary":"格隆汇10月27日丨ST诺泰(688076.SH)发布2026年三季报显示，公司前三季实现营业收入17.47亿元，同比增长14.43%；归母净利润3.35亿元，同比下滑24.61%；扣非归母净利润3.72亿元，同比下滑14.89%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20261027/32409343.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["688076"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669463622","title":"ST诺泰3865万收购亏损赛立成：关联收购暗藏多重疑云","url":"https://stock-news.laohu8.com/highlight/detail?id=2669463622","media":"新浪证券","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669463622?lang=zh_cn&edition=full","pubTime":"2026-09-24 16:35","pubTimestamp":1790238900,"startTime":"0","endTime":"0","summary":"近日，生物医药企业ST诺泰（维权）抛出一笔折价关联收购，拟由子公司澳赛诺以3865万元现金收购赛立成100%股权。赛立成由原增塑剂企业转型原料药制造，转型不及预期，原有业务停产，现金流恶化。财务数据显示，赛立成2025年净利润亏损1586.91万元，2026年一季度继续亏损80.92万元，经营并未走出困境。针对持续亏损标的的关联交易，业绩承诺是重要风险约束，缺失该机制，难以规避利益输送、风险向上市公司转移的隐患。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/aigcy/2026-09-24/doc-inisxnux8180709.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688076","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669580454","title":"诺泰生物收购赛立成意欲何为？","url":"https://stock-news.laohu8.com/highlight/detail?id=2669580454","media":"中金财经","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669580454?lang=zh_cn&edition=full","pubTime":"2026-09-24 13:58","pubTimestamp":1790229523,"startTime":"0","endTime":"0","summary":"9月15日，多肽和寡核苷酸等细分领域的领先医药上市公司诺泰生物发布公告称，公司全资子公司拟以现金收购浙江赛立成生物科技有限公司100%股权，交易总价3865万元，本次交易构成关联交易。 在杭州环保指标硬约束下，诺泰建德工厂虽订单饱满，扩产却无从落地，收购相邻的赛立成存量产能成为破局路径。值得关注的是，本次交易折价约18.81%，不形成商誉，且因标的已停业而未设业绩承诺，符合监管规则。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/shichangjuejin/20260924/32380177.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["688076","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669435366","title":"股市必读：ST诺泰生物（688076）9月23日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2669435366","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669435366?lang=zh_cn&edition=full","pubTime":"2026-09-24 02:54","pubTimestamp":1790189652,"startTime":"0","endTime":"0","summary":"截至2026年9月23日收盘，ST诺泰生物报收于29.06元，上涨1.82%，换手率0.89%，成交量2.83万手，成交额8192.73万元。当日关注点交易信息汇总：9月23日主力资金净流入86.39万元，占总成交额1.05%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400002756.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688076","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669648262","title":"ST诺泰：9月23日召开业绩说明会，投资者参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2669648262","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669648262?lang=zh_cn&edition=full","pubTime":"2026-09-23 23:02","pubTimestamp":1790175724,"startTime":"0","endTime":"0","summary":"证券之星消息，2026年9月23日ST诺泰发布公告称公司于2026年9月23日召开业绩说明会。ST诺泰2026年中报显示，上半年度公司主营收入11.4亿元，同比上升8.72%；归母净利润2.15亿元，同比下降30.64%；扣非净利润2.49亿元，同比下降18.6%；其中2026年第二季度，公司单季度主营收入5.87亿元，同比上升21.55%；单季度归母净利润8558.67万元，同比下降45.64%；单季度扣非净利润1.25亿元，同比下降19.41%；负债率56.12%，投资收益146.58万元，财务费用5178.09万元，毛利率59.5%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092300041689.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688076"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667465646","title":"ST诺泰(688076.SH)子公司拟3865万元收购赛立成100%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2667465646","media":"智通财经","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667465646?lang=zh_cn&edition=full","pubTime":"2026-09-15 18:17","pubTimestamp":1789467454,"startTime":"0","endTime":"0","summary":"智通财经APP讯，ST诺泰 发布公告，公司全资子公司杭州澳赛诺生物科技有限公司拟以现金收购安吉星特企业管理合伙企业、杭州健逸医药科技有限公司、潘余有、潘余明、王文松合计持有的浙江赛立成生物科技有限公司100%股权，交易总价为3865万元。交易完成后，赛立成将成为公司全资孙公司，纳入公司合并报表范围。公司全资子公司澳赛诺位于浙江省杭州市建德市下涯镇丰和路18号，是一家以小分子定制研发生产为主的生物医药企业。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1496318.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688076"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662740280","title":"ST诺泰（688076）2026年中报简析：增收不增利","url":"https://stock-news.laohu8.com/highlight/detail?id=2662740280","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662740280?lang=zh_cn&edition=full","pubTime":"2026-08-27 06:17","pubTimestamp":1787782636,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期ST诺泰发布2026年中报。根据财报显示，ST诺泰增收不增利。截至本报告期末，公司营业总收入11.4亿元，同比上升8.72%，归母净利润2.15亿元，同比下降30.64%。财报体检工具显示：建议关注公司现金流状况建议关注公司债务状况建议关注公司应收账款状况本文数据来源于ST诺泰2026年中报，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082700011345.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688076","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662794907","title":"ST诺泰(688076)6月30日股东户数1.39万户，较上期减少7.73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662794907","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662794907?lang=zh_cn&edition=full","pubTime":"2026-08-26 17:36","pubTimestamp":1787736966,"startTime":"0","endTime":"0","summary":"证券之星消息，近日ST诺泰披露，截至2026年6月30日公司股东户数为1.39万户，较3月31日减少1160.0户，减幅为7.73%。在化学制药行业个股中，ST诺泰股东户数低于行业平均水平，截至6月30日，化学制药行业平均股东户数为3.68万户。从股价来看，2026年3月31日至2026年6月30日，ST诺泰区间跌幅为6.26%，在此期间股东户数减少1160.0户，减幅为7.73%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600039463.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688076","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662706768","title":"股市必读：ST诺泰新发布《ST诺泰：关于会计政策变更的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2662706768","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662706768?lang=zh_cn&edition=full","pubTime":"2026-08-26 07:40","pubTimestamp":1787701228,"startTime":"0","endTime":"0","summary":"截至2026年8月25日收盘，ST诺泰报收于27.93元，上涨2.91%，换手率0.85%，成交量2.69万手，成交额7423.42万元。公司公告汇总ST诺泰：关于会计政策变更的公告公司根据财政部《企业会计准则解释第19号》《企业会计准则解释第20号》要求，自2026年1月1日起变更会计政策，涉及非同一控制下企业合并中补偿性资产的会计处理、金融资产合同现金流量特征评估等内容；该变更无需提交董事会及股东会审议，不会对公司财务状况、经营成果和现金流量产生重大影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600012638.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688076","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662751673","title":"图解ST诺泰中报：第二季度单季净利润同比下降45.64%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662751673","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662751673?lang=zh_cn&edition=full","pubTime":"2026-08-26 02:42","pubTimestamp":1787683371,"startTime":"0","endTime":"0","summary":"证券之星消息，ST诺泰2026年中报显示，上半年度公司主营收入11.4亿元，同比上升8.72%；归母净利润2.15亿元，同比下降30.64%；扣非净利润2.49亿元，同比下降18.6%；其中2026年第二季度，公司单季度主营收入5.87亿元，同比上升21.55%；单季度归母净利润8558.67万元，同比下降45.64%；单季度扣非净利润1.25亿元，同比下降19.41%；负债率56.12%，投资收益146.58万元，财务费用5178.09万元，毛利率59.5%。财报数据概要请见下图:本文数据来源于ST诺泰2026年中报，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600005287.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688076"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661211451","title":"每周股票复盘：ST诺泰（688076）现1400万元大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2661211451","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661211451?lang=zh_cn&edition=full","pubTime":"2026-08-23 02:15","pubTimestamp":1787422513,"startTime":"0","endTime":"0","summary":"截至2026年8月21日收盘，ST诺泰（688076）报收于27.33元，较上周的28.24元下跌3.22%。本周，ST诺泰8月20日盘中最高价报30.35元。8月19日盘中最低价报26.8元。ST诺泰当前最新总市值86.59亿元，在化学制药板块市值排名57/149，在两市A股市值排名2033/5210。本周关注点来自交易信息汇总：ST诺泰8月21日发生1400万元大宗交易交易信息汇总8月21日ST诺泰现1400万元大宗交易以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082300000381.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688076","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661526445","title":"8月21日ST诺泰现1400万元大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2661526445","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661526445?lang=zh_cn&edition=full","pubTime":"2026-08-21 18:27","pubTimestamp":1787308076,"startTime":"0","endTime":"0","summary":"证券之星消息，8月21日ST诺泰发生大宗交易，交易数据如下：近三个月该股共发生2笔大宗交易，合计成交5000.0手，溢价成交2笔。该股近期无解禁股上市。截至2026年8月21日收盘，ST诺泰(688076)报收于27.33元，下跌3.09%，换手率2.18%，成交量6.89万手，成交额1.89亿元。该股最近90天内共有1家机构给出评级，买入评级1家。本文数据来源于上海证券交易所大宗交易信息披露，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082100034480.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688076"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651166308","title":"股市必读：ST诺泰（688076）新发布《中喜会计师事务所（特殊普通合伙）关于江苏诺泰澳赛诺生物制药股份有限公司2025年年度报告及2026年第一季度报告的信息披露监管问询函有关财务问题的回复》","url":"https://stock-news.laohu8.com/highlight/detail?id=2651166308","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651166308?lang=zh_cn&edition=full","pubTime":"2026-07-13 02:12","pubTimestamp":1783879932,"startTime":"0","endTime":"0","summary":"截至2026年7月10日收盘，ST诺泰报收于28.54元，上涨0.85%，换手率0.84%，成交量2.65万手，成交额7590.9万元。公司公告汇总：ST诺泰就上交所关于2025年年报及2026年一季报的信息披露监管问询函作出回复，年审会计师确认收入确认真实准确、资产减值准备计提充分。公司公告汇总：中喜会计师事务所就财务相关问询出具专项回复，披露公司2025年营收19.43亿元、归母净利润3.32亿元，2026年一季度净利润1.29亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071300001117.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688076"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649994140","title":"ST诺泰（688076）披露2023年限制性股票激励计划第三个归属期归属结果暨股份上市公告，7月8日股价下跌0.91%","url":"https://stock-news.laohu8.com/highlight/detail?id=2649994140","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649994140?lang=zh_cn&edition=full","pubTime":"2026-07-08 22:37","pubTimestamp":1783521434,"startTime":"0","endTime":"0","summary":"截至2026年7月8日收盘，ST诺泰报收于28.45元，较前一交易日下跌0.91%，最新总市值为89.92亿元。近日，ST诺泰发布《关于2023年限制性股票激励计划第三个归属期归属结果暨股份上市公告》。公告显示，公司完成2023年限制性股票激励计划第三个归属期的股份归属登记，本次归属股份数量为764,064股，来源为公司向激励对象定向发行A股普通股股票，归属对象共58人，包括董事、高级管理人员、核心技术人员及其他激励对象。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070800043033.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688076","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646931574","title":"每周股票复盘：ST诺泰（688076）第三期限制性股票归属76.4万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2646931574","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2646931574?lang=zh_cn&edition=full","pubTime":"2026-06-28 03:52","pubTimestamp":1782589932,"startTime":"0","endTime":"0","summary":"截至2026年6月26日收盘，ST诺泰报收于26.25元，较上周的27.43元下跌4.3%。本周，ST诺泰6月23日盘中最高价报28.75元。ST诺泰当前最新总市值82.96亿元，在化学制药板块市值排名54/150，在两市A股市值排名2188/5206。本周关注点公司公告汇总：ST诺泰第三期限制性股票归属76.4064万股，58人符合归属条件。本次可归属数量为76.4064万股，归属人数为58人，股票来源为公司向激励对象定向发行A股普通股。本次合计作废处理限制性股票5.768万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062800001220.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688076"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646366369","title":"ST诺泰（688076）披露2023年限制性股票激励计划第三个归属期符合归属条件的公告，6月26日股价下跌1.72%","url":"https://stock-news.laohu8.com/highlight/detail?id=2646366369","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2646366369?lang=zh_cn&edition=full","pubTime":"2026-06-26 22:58","pubTimestamp":1782485898,"startTime":"0","endTime":"0","summary":"截至2026年6月26日收盘，ST诺泰报收于26.25元，较前一交易日下跌1.72%，最新总市值为82.96亿元。该股当日开盘26.7元，最高27.49元，最低26.19元，成交额达5156.86万元，换手率为0.62%。近日，ST诺泰发布《关于公司2023年限制性股票激励计划第三个归属期符合归属条件的公告》。公司层面业绩考核达标，2025年营业收入增长率达198.30%，满足第三个归属期目标值要求，公司层面归属比例为100%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062600046131.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688076","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640972060","title":"ST诺泰：公司自主研发的英克司兰注射液目前处于小试阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2640972060","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2640972060?lang=zh_cn&edition=full","pubTime":"2026-06-03 16:27","pubTimestamp":1780475256,"startTime":"0","endTime":"0","summary":"证券之星消息，ST诺泰(688076)06月03日在投资者关系平台上答复投资者关心的问题。投资者提问：公司有英克司兰原料药的技术，建议公司开发相当于英克司兰的长效降脂药物品种，在小核酸方向主攻研发创新药，加大研发。祝公司越来越好。ST诺泰回复：尊敬的投资者您好，公司自主研发的英克司兰注射液目前处于小试阶段，具体您可查阅公司2025年年度报告-在研项目情况，感谢您的关注与建议！本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060300033193.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688076","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640722199","title":"ST诺泰：已与Incyte、Gilead等知名创新药企建立稳固合作关系","url":"https://stock-news.laohu8.com/highlight/detail?id=2640722199","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2640722199?lang=zh_cn&edition=full","pubTime":"2026-06-03 16:27","pubTimestamp":1780475250,"startTime":"0","endTime":"0","summary":"证券之星消息，ST诺泰(688076)06月03日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘你好 近日看到信达与辉瑞签订超100亿美元的肿瘤药物研发合同，我想请问诺泰生物何时能具备与国际大厂签订药物研发计划的能力？ST诺泰回复：尊敬的投资者您好，公司已与Incyte、Gilead等知名创新药企建立了稳固的合作关系，公司会在定期报告中披露已签署重要订单情况。此外，公司如签订达到《上海证券交易所科创板股票上市规则》中规定的重大合同披露标准的订单合同，会及时履行信息披露义务，感谢您的关注！本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060300033187.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","159992","BK0239","688076","BK1574","06978"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1794559400402,"stockEarnings":[{"period":"1week","weight":0.0236},{"period":"1month","weight":-0.0116},{"period":"3month","weight":-0.0028},{"period":"6month","weight":-0.0883},{"period":"1year","weight":-0.2869},{"period":"ytd","weight":-0.2433}],"compareEarnings":[{"period":"1week","weight":-0.0092},{"period":"1month","weight":-0.0382},{"period":"3month","weight":-0.0691},{"period":"6month","weight":-0.116},{"period":"1year","weight":-0.0861},{"period":"ytd","weight":-0.0789}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"江苏诺泰澳赛诺生物制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"14086人(较上一季度增加1.66%)","perCapita":"22491股","listingDate":"2021-05-20","address":"江苏省连云港市连云区经济技术开发区临浦路28号","registeredCapital":"31681万元","survey":" 江苏诺泰澳赛诺生物制药股份有限公司的主营业务是多肽药物及小分子化药的自主研发与定制研发生产。公司的主要产品是司美格鲁肽、利拉鲁肽、替尔泊肽、英克司兰、醋酸兰瑞肽、磷酸奥司他韦、胸腺法新。","listedPrice":15.57},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ST诺泰(688076)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供ST诺泰(688076)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"ST诺泰,688076,ST诺泰股票,ST诺泰股票老虎,ST诺泰股票老虎国际,ST诺泰行情,ST诺泰股票行情,ST诺泰股价,ST诺泰股市,ST诺泰股票价格,ST诺泰股票交易,ST诺泰股票购买,ST诺泰股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ST诺泰(688076)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供ST诺泰(688076)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}